These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 22021864)

  • 1. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.
    Holle JU; Dubrau C; Herlyn K; Heller M; Ambrosch P; Noelle B; Reinhold-Keller E; Gross WL
    Ann Rheum Dis; 2012 Mar; 71(3):327-33. PubMed ID: 22021864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.
    Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D
    Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.
    Cartin-Ceba R; Golbin JM; Keogh KA; Peikert T; Sánchez-Menéndez M; Ytterberg SR; Fervenza FC; Specks U
    Arthritis Rheum; 2012 Nov; 64(11):3770-8. PubMed ID: 22730028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre.
    Besada E; Koldingsnes W; Nossent JC
    Rheumatology (Oxford); 2013 Nov; 52(11):2041-7. PubMed ID: 23934313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.
    Calich AL; Puéchal X; Pugnet G; London J; Terrier B; Charles P; Mouthon L; Guillevin L;
    J Autoimmun; 2014 May; 50():135-41. PubMed ID: 24703438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
    Pullerits R; Ljevak M; Vikgren J; Bokarewa M
    Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis.
    Roubaud-Baudron C; Pagnoux C; Méaux-Ruault N; Grasland A; Zoulim A; LE Guen J; Prud'homme A; Bienvenu B; de Menthon M; Camps S; LE Guern V; Aouba A; Cohen P; Mouthon L; Guillevin L;
    J Rheumatol; 2012 Jan; 39(1):125-30. PubMed ID: 22089465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener's): a retrospective single-center study.
    Azar L; Springer J; Langford CA; Hoffman GS
    Arthritis Rheumatol; 2014 Oct; 66(10):2862-70. PubMed ID: 24943239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage.
    Holle JU; Voigt C; Both M; Holl-Ulrich K; Nölle B; Laudien M; Moosig F; Gross WL
    Rheumatology (Oxford); 2013 May; 52(5):875-82. PubMed ID: 23293138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Severe Wegener's granulomatosis successfully treated with rituximab].
    Semenkova EN; Krivosheev OG; Novikov PI; Osipenko VI; Nosova NR; Parfenova SA; Nikiforova NV; Borodin OO
    Ter Arkh; 2010; 82(6):53-5. PubMed ID: 20731113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wegener granulomatosis (granulomatosis with polyangiitis): evolving concepts in treatment.
    Lynch JP; Tazelaar H
    Semin Respir Crit Care Med; 2011 Jun; 32(3):274-97. PubMed ID: 21674414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage?
    Holle JU; Gross WL; Holl-Ulrich K; Ambrosch P; Noelle B; Both M; Csernok E; Moosig F; Schinke S; Reinhold-Keller E
    Ann Rheum Dis; 2010 Nov; 69(11):1934-9. PubMed ID: 20511614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations.
    Aries PM; Hellmich B; Voswinkel J; Both M; Nölle B; Holl-Ulrich K; Lamprecht P; Gross WL
    Ann Rheum Dis; 2006 Jul; 65(7):853-8. PubMed ID: 16269425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease.
    Sánchez-Cano D; Callejas-Rubio JL; Ortego-Centeno N
    J Clin Rheumatol; 2008 Apr; 14(2):92-3. PubMed ID: 18391678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
    Pagnoux C; Mahr A; Hamidou MA; Boffa JJ; Ruivard M; Ducroix JP; Kyndt X; Lifermann F; Papo T; Lambert M; Le Noach J; Khellaf M; Merrien D; Puéchal X; Vinzio S; Cohen P; Mouthon L; Cordier JF; Guillevin L;
    N Engl J Med; 2008 Dec; 359(26):2790-803. PubMed ID: 19109574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Otolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab.
    Malm IJ; Mener DJ; Kim J; Seo P; Kim YJ
    Otolaryngol Head Neck Surg; 2014 Jan; 150(1):68-72. PubMed ID: 24154746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experience with rituximab treatment (monoclonal antibodies to B-lymphocyte CD20 receptors) of Wegener's granulomatosis patients with renal impairment].
    Novikov PI; Krivosheev OG; Semenkova EN
    Ter Arkh; 2011; 83(11):70-6. PubMed ID: 22312891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
    Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
    J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower doses of rituximab in remission induction for refractory granulomatosis with polyangiitis.
    Wawrzycka-Adamczyk K; Zugaj A; Włudarczyk A; Kosałka J; Sznajd J; Bazan-Socha S; Musiał J
    Przegl Lek; 2014; 71(12):663-5. PubMed ID: 25951692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.